Edition:
India

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

2.97USD
15 Jun 2018
Change (% chg)

$-0.02 (-0.67%)
Prev Close
$2.99
Open
$2.99
Day's High
$3.02
Day's Low
$2.95
Volume
762,303
Avg. Vol
349,137
52-wk High
$5.66
52-wk Low
$2.60

Select another date:

Wed, May 2 2018

BRIEF-Achillion Pharma Says Truitt Gets Annualized Base Salary Of $560,000

* ACHILLION PHARMACEUTICALS SAYS JOSEPH TRUITT RECEIVES ANNUALIZED BASE SALARY OF $560,000, IN CONNECTION WITH APPOINTMENT AS CEO - SEC FILING

BRIEF-Achillion Reports Q1 Loss Per Share $0.15

* ACHILLION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND MANAGEMENT TRANSITION

BRIEF-Achillion Announces ACH-4471 Receives Positive Opinion For Orphan Drug Status In EU For The Treatment Of C3 Glomerulopathy

* ACHILLION ANNOUNCES ACH-4471 RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR THE TREATMENT OF C3 GLOMERULOPATHY

BRIEF-Achillion Forecasts 2018 Loss Of $0.55-$0.58 Per Share

* ACHILLION ANNOUNCES RESTRUCTURING TO ADVANCE CORPORATE STRATEGY; ANNOUNCES 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-Achillion Initiates Phase I First-In Study Of ACH-5228

* ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D

BRIEF-Achillion Announces ACH-4471 Granted Orphan Drug Designation For The Treatment Of C3 Glomerulopathy

* ACHILLION ANNOUNCES ACH-4471 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF C3 GLOMERULOPATHY (C3G) AND THE INITIATION OF A PHASE 1 EXTENDED-RELEASE BIOAVAILABILITY STUDY

Select another date: